Back HCV Populations

Interferon-Free Hepatitis C Treatment Safe and Effective for People Who Inject Drugs

Chronic hepatitis C patients on opioid substitution therapy, including those who continue to use illicit drugs, maintained good adherence and had high sustained response rates when treated with sofosbuvir/ledipasvir (Harvoni) or sofosbuvir/velpatasvir (Epclusa), according to a pair of ad-hoc analyses published in the August online edition of Clinical Infectious Diseases.

alt

Read more:

EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains

People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona. However, the same study saw several cases of hepatitis C virus (HCV) reinfection after a cure, suggesting a greater emphasis on prevention may be warranted.

alt

Read more:

Coverage of 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015)

Hepatitis C treatment for people who inject drugs, including those receiving opioid substitution therapy (OST), was a major theme of the 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015), October 7-9 in Sydney. 

INHSU 2015 Highlights Hepatitis C Prevention and Treatment for People Who Inject Drugs

INHSU 2015: HCV Treatment Works Well for People Who Inject Drugs, but Barriers to Access Remain

INHSU website

10/16/15

alt